Skip to main content
. 2016 Aug 19;7:12528. doi: 10.1038/ncomms12528

Figure 3. Targeting myeloid cell VEGF-A enhances chemotherapy-induced senescence and immune cell recruitment.

Figure 3

(a) Representative images of untreated and CDDP-treated tumour sections showing SA-β-gal-activity at pH 6.0 at indicated time points. (b) Quantification of SA-β-gal-positive cells shown in a (untreated, n≥4; CDDP, n≥6). (c) Flow cytometric analysis of cisplatin-treated LLC tumours showing percentages of tumour-infiltrating NKp46/NK1.1-, CD4-, CD8- and F4/80-positive cells among CD45 cells at indicated time points (representative of three independent experiments). The full gating strategy is shown in Supplementary Fig. 9. Bars represent mean values; error bars indicate the s.e.m.; statistical significance was determined by one-way analysis of variance followed by Bonferroni post-hoc test when more than two groups were compared. Statistical significance is indicated as *P<0.05, **P<0.01 and ***P<0.001. Scale bar, 100 μm.